Floatz logo

Eloxatin

Bile Duct Carcinoma

University of WashingtonPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Bile Duct Carcinoma cohort.

Asset / SponsorPhaseRating
Capecitabine
University of Washington
Phase 1CC
cgx1321
Curegenix Inc.
Phase 1CC
[18f]f-resca-g5
RenJi Hospital
N/AD
[18f]f-resca-wwh347
RenJi Hospital
N/AD
[68Ga]Ga-NOTA-WWH347
RenJi Hospital
N/AD

View all 12 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →